Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 62.86M | P/E | - | EPS this Y | 46.30% | Ern Qtrly Grth | - |
| Income | -26.3M | Forward P/E | -2.58 | EPS next Y | 14.90% | 50D Avg Chg | -14.00% |
| Sales | 895.48k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -34.00% |
| Dividend | N/A | Price/Book | 6.29 | EPS next 5Y | - | 52W High Chg | -63.00% |
| Recommedations | 2.50 | Quick Ratio | 0.80 | Shares Outstanding | 21.89M | 52W Low Chg | 29.00% |
| Insider Own | 21.63% | ROA | -93.42% | Shares Float | 18.39M | Beta | 0.12 |
| Inst Own | 0.47% | ROE | -303.20% | Shares Shorted/Prior | 720.64K/324.52K | Price | 4.11 |
| Gross Margin | 56.92% | Profit Margin | - | Avg. Volume | 25,011 | Target Price | 2.00 |
| Oper. Margin | -3,068.71% | Earnings Date | Oct 2 | Volume | 36,528 | Change | 0.49% |
About Mainz Biomed N.V.
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.
Mainz Biomed N.V. News